Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7549)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Nov 27, 2020 (publication date) through May 10, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Broquetas T, Garcia-Retortillo M, Micó M, Canillas L, Puigvehí M, Cañete N, Coll S, Viu A, Hernandez JJ, Bessa X, Carrión JA. Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients. World J Hepatol 2020; 12(11): 1076-1088 [PMID: 33312431 DOI: 10.4254/wjh.v12.i11.1076] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v12/i11/1076.htm |
| Number | Citing Articles |
| 1 |
Teresa Broquetas, Juan-Jose Hernandez, Montserrat Garcia-Retortillo, Lidia Canillas, Marc Puigvehí, Nuria Cañete, Susanna Coll, Ana Viu, Esther Garrido, Miquel Mico, Xavier Bessa, José A. Carrión. On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty. Digestive and Liver Disease 2022; 54(8): 1044 doi: 10.1016/j.dld.2021.12.017
|
| 2 |
Margarita Papatheodoridi, George Papatheodoridis. Hepatitis B Virus and Liver Disease. 2021; : 267 doi: 10.1007/978-981-16-3615-8_12
|
| 3 |
Yan-jie Lin, Fang-fang Sun, Zhan Zeng, Xiao-yue Bi, Liu Yang, Ming-hui Li, Yao Xie. Combination and Intermittent Therapy Based on Pegylated Interferon Alfa-2a for Chronic Hepatitis B with Nucleoside (Nucleotide) Analog-Experienced Resulting in Hepatitis B Surface Antigen Clearance: A Case Report. Viral Immunology 2022; 35(1): 71 doi: 10.1089/vim.2021.0112
|
| 4 |
Hui Li, Caie Wang, Lu Chai, Xingshun Qi. Combination treatment of pegylated interferon and tenofovir versus tenofovir for people with chronic hepatitis B. Cochrane Database of Systematic Reviews 2023; 2023(8) doi: 10.1002/14651858.CD015730
|
| 5 |
Teresa Broquetas, José A Carrión. Past, present, and future of long-term treatment for hepatitis B virus. World Journal of Gastroenterology 2023; 29(25): 3964-3983 doi: 10.3748/wjg.v29.i25.3964
Abstract(970) |
Core Tip(793) |
Full Article(HTML)(6092)
|
Full Article with Cover (PDF)-2143K(183)
|
Full Article (Word)-469K(49)
|
Audio-340K(6)
|
Peer-Review Report-317K(80)
|
Answering Reviewers-65K(84)
|
Full Article (PDF)-890K(441)
|
Full Article (XML)-395K(83)
|
Times Cited (12)
|
Total Visits (12287)
|
Open
|
| 6 |
Wenting Zhong, Lanzhi Yan, Yage Zhu, Lei Shi, Yingli He, Tianyan Chen, Jie Zheng. A high functional cure rate was induced by pegylated interferon alpha-2b treatment in postpartum hepatitis B e antigen-negative women with chronic hepatitis B virus infection: an exploratory study. Frontiers in Cellular and Infection Microbiology 2024; 14 doi: 10.3389/fcimb.2024.1426960
|
| 7 |
Huiqing Liang, Xiaoting Zheng, Qianguo Mao, Jiaen Yang, Qingfa Ruan, Chuncheng Wu, Yaoyu Liu, Siyan Chen, Luyun Zhang, Manying Zhang, Hongli Zhuang, Li Lin, Shaodong Chen, Hyun Jin Kwun. Comparative efficacy and safety of pegylated interferon-alpha monotherapy vs combination therapies with entecavir or tenofovir in chronic hepatitis B patients. Microbiology Spectrum 2025; 13(5) doi: 10.1128/spectrum.02694-24
|
| 8 |
Shuang Xu, Xiao-Ting Ye, Dong Zhang, Pu Dong, Yang-He Wu, Chen-Wei Pan. Predicting clinical outcomes in chronic hepatitis B patients receiving nucleoside analogues and pegylated interferon alpha: a hematochemical and clinical analysis. BMC Infectious Diseases 2024; 24(1) doi: 10.1186/s12879-024-10057-0
|
| 9 |
Rafaela Pires da Silva, João Ismael Budelon Gonçalves, Rafael Fernandes Zanin, Felipe Barreto Schuch, Ana Paula Duarte de Souza. Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.657363
|
| 10 |
Mariem Znaidia, Caroline Demeret, Sylvie van der Werf, Anastassia V. Komarova. Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options. Viruses 2022; 14(6): 1247 doi: 10.3390/v14061247
|
| 11 |
Yujing Li, Fada Wang, Jing Zhou, Lanqing Li, Chengrun Song, Enqiang Chen. Optimal Treatment Based on Interferon No Longer Makes Clinical Cure of Chronic Hepatitis B Far Away: An Evidence‐Based Review on Emerging Clinical Data. Clinical Pharmacology & Therapeutics 2024; 116(2): 295 doi: 10.1002/cpt.3287
|
| 12 |
Yan Peng, Mingzhe Ma, Ting Liu, Wenmin He, Shutao Lin, Wa Zhong, Xiaohui Min. Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients treated with nucleotide analogs plus polyethylene glycol interferon. Frontiers in Medicine 2025; 11 doi: 10.3389/fmed.2024.1510230
|
| 13 |
Teresa Broquetas, José A Carrión. Current Perspectives on Nucleos(t)ide Analogue Therapy for the Long-Term Treatment of Hepatitis B Virus. Hepatic Medicine: Evidence and Research 2022; : 87 doi: 10.2147/HMER.S291976
|